Q32 Bio Dividend per Share

What does Q32 Bio do? Homology Medicines, Inc. generates revenue by developing and commercializing treatments for rare diseases at the genetic level. The company operates as a technology platform focused on creating a pipeline of new medicines that address and cure the underlying cause of monogenic diseases. Its lead product candidate, HMI-102, is a gene therapy designed for the treatment of phenylketonuria (PKU), with the PKU program specifically targeting adults using this gene therapy approach. The firm utilizes its suite of 15 adeno-associated virus vectors (AAVHSCs) to enable a method of gene editing called gene correction, allowing for precise targeting of disease-relevant tissues across both gene editing and gene therapy modalities. Q32 Bio is one of the most popular companies on Eulerpool.